



US010751348B2

(12) **United States Patent**  
**Josephs et al.**

(10) **Patent No.:** **US 10,751,348 B2**  
(45) **Date of Patent:** **\*Aug. 25, 2020**

(54) **FORMULATIONS OF TESTOSTERONE AND METHODS OF TREATMENT THEREWITH**

(71) Applicants: **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM**, Austin, TX (US); **MEDCARA PHARMACEUTICALS, LLC**, Conrad, IA (US)

(72) Inventors: **Robert A. Josephs**, Austin, TX (US); **Craig Herman**, Cedar Rapids, IA (US)

(73) Assignees: **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM**, Austin, TX (US); **MEDCARA PHARMACEUTICALS, LLC**, Conrad, IA (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.  
This patent is subject to a terminal disclaimer.

(21) Appl. No.: **16/382,607**

(22) Filed: **Apr. 12, 2019**

(65) **Prior Publication Data**

US 2019/0298736 A1 Oct. 3, 2019

**Related U.S. Application Data**

(63) Continuation of application No. 15/507,246, filed as application No. PCT/US2015/047385 on Aug. 28, 2015, now Pat. No. 10,258,631.

(Continued)

(51) **Int. Cl.**

**A61K 31/5685** (2006.01)

**A61K 45/06** (2006.01)

(Continued)

(52) **U.S. Cl.**

CPC ..... **A61K 31/5685** (2013.01); **A61K 9/0043** (2013.01); **A61K 9/107** (2013.01);  
(Continued)

(58) **Field of Classification Search**

None  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

5,756,071 A 5/1998 Mattern et al.  
6,280,770 B1 8/2001 Pather et al.  
(Continued)

**FOREIGN PATENT DOCUMENTS**

WO 2006/113505 \* 10/2006  
WO 2006/113505 10/2006  
WO 2011/129812 10/2011

**OTHER PUBLICATIONS**

"Natesto (testosterone) nasal gel CIII", dated May 1, 2014, from [www.accessdata.fda.gov/drugatfda\\_docs/label/201/205488s0001bl.pdf](http://www.accessdata.fda.gov/drugatfda_docs/label/201/205488s0001bl.pdf) (retrieved on Jan. 19, 2018).

(Continued)

*Primary Examiner* — Karl J Puttlitz

(74) *Attorney, Agent, or Firm* — Parker Highlander PLLC

(57) **ABSTRACT**

The present disclosure relates to novel pharmaceutical composition for the administration of testosterone or testosterone derivatives. The present disclosure also provides methods of treatment of diseases and disorders associated with fear and anxiety, a decrease in libido, or hypogonadism.

**19 Claims, 7 Drawing Sheets**

